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Domestic Intestinal Parasite Guidelines  
Presumptive Treatment and Screening for Strongyloidiasis, Schistosomiasis and 
Infections Caused by Soil-Transmitted Helminths for Refugees  
Introduction  
It is estimated that more than one billion people are infected with soil-transmitted helminths (STH), 200 
million with Schistosoma spp., and 100 million with Strongyloides.
1,2,3
  These parasites are some of the most 
common infections in refugees.
4,5
 Although frequently asymptomatic or sub-clinical, these infections may 
cause significant illness and even result in death.  Parasites that infect humans represent a very complex 
and broad category of organisms.  This section of the guidelines will address the parasitic infections most 
commonly encountered in refugees but will focus on soil-transmitted helminthic infections (Ascaris, Trichuris, 
hookworm), Strongyloides, and Schistosoma spp.  
Epidemiology  
Most refugees are at risk for parasitic infection.  Prevalence data for parasitic infections in refugees in the 
United States are largely derived from stool and serologic surveys. These surveys have revealed high rates 
of certain infections in most refugee populations such as soil-transmitted helminth infections, Strongyloides 
and intestinal protozoal infections.  In addition, they also show that there are some parasitic infections that 
are more frequently observed in certain populations such as Schistosoma spp. infections in sub-Saharan 
African (SSA) refugees.  The overall prevalence of potentially pathogenic parasites among refugees 
resettled in North America has been reported to range from 8% to 86%.
4,5
 This broad range can be 
explained by differences in geographic origin, age, living conditions (including quality of drinking water, 
sanitation, and access to footwear), dietary habits, occupational history, education level, and previous 
countries of exposure/asylum in the populations studies.
5
  In addition, the variation  in prevalence may be 




Since the initiation of presumptive predeparture albendazole (1999), prevalence of soil-transmitted helminths 
detected among refugees following arrival in the United States have dramatically decreased.
8,9
 However, the 
regimen of a single dose of albendazole has little or no effect against other important parasitic infections.  Of 
particular concern are two parasitic infections commonly encountered in refugee populations: Strongyloides 
stercoralis (nematode) and Schistosoma spp. (trematode). Strongyloides infection is found in many refugee 
populations but is particularly prevalent among Southeast Asian refugees. Schistosoma spp. infections are 
encountered predominantly in SSA refugees. The prevalence of these parasitic infections was initially under-
recognized since most early studies utilized only routine stool testing, a poor technique for detection of these 
particular organisms.
9-12
 Both strongyloidiasis and schistosomiasis are considered chronic infections and 
both have been associated with morbidity and mortality years after migration.  
As many as 100 million persons worldwide are estimated to be chronically infected with 
Strongyloides.5 Prevalence in serosurveys of refugee populations range from 11–69% infected. Unlike most 
parasitic infections which are unable to replicate in the human host, Strongyloides is able to replicate and 
auto-infect causing infection that may persist for decades.  If the condition is not detected promptly after 
arrival, data indicate that the average time to diagnosis in the United States is more than 5 years after 
migration.
11 
In fact, one study found that 24% of Laotian refugees had continued strongyloidiasis an average 
of 12 years after migration.9 Strongyloides hyperinfection syndrome may occur many years after migration to 
a non-endemic setting, with case reports occurring >50 years after last known exposure.
15-17
   Hyperinfection 
syndrome, triggered when large numbers of parasites infiltrate internal organs, results in fatality rates 
exceeding 50%.  The syndrome is generally induced when an individual is placed on corticosteroids 
although other immunosuppressive conditions such as cancer and transplant chemotherapeutic 
immunosuppression may also trigger hyperinfection syndrome. 
15, 17
  
More than 200 million people worldwide are estimated to be infected with schistosomiasis.  The 
seroprevalence in SSA refugees ranges from 15-46%.  Infection with schistosomiasis may persist in humans 
for more than 25 years and has been associated with many sequelae depending on the species, the 
parasite load and the host response.   Schistosomiasis is associated with liver cirrhosis and resulting clinical 
complications (S. mansoni, S. japonicum), squamous cell carcinoma of the bladder (S. haematobium), and 
urinary tract obstruction and renal failure (S. haematobium).  Potentially devastating clinical manifestations 
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occasionally occur when the parasite egg enters the systemic circulation and travels to a normally sterile site 
within the body, causing severe inflammation. Eggs may travel to any part of the body, including the brain 
and spinal cord where the inflammatory response to the egg may cause paralysis or myelitis.   
History and evolution of the predeparture presumptive treatment for parasites in US-bound refugees  
In 1997, a CDC pilot project evaluated single dose albendazole presumptive treatment in U.S.-bound 
Barawan Somali refugees.  This project demonstrated decreases in soil-transmitted parasites with 
presumptive treatment.  In May 1999, CDC extended this recommendation to all refugees resettling from 
Africa and Asia. In 2008 the recommendation was extended to refugees from the Middle East.  Currently, 
most refugees from these countries without a contraindication are receiving a single dose of albendazole 
prior to departure. A table of countries that are currently implementing these pre-departure presumptive 
treatments can be found here. 
Data increasingly suggest that predeparture albendazole treatment has dramatically decreased the overall 
prevalence of soil-transmitted helminth infections in refugees.  A recent evaluation of more than 26,000 
African and Asian refugees demonstrated single dose albendazole resulted in an absolute reduction of the 
prevalence of any soil-transmitted helminth from 20.8% to 4.7% as measured by stool ova and parasite 
(O&P) examination. Albendazole-treated refugees were less likely than untreated refugees to have any 
nematode (prevalence ratio (PR), 0.19), Ascaris (PR 0.06), hookworm (PR 0.07), or Trichuris (PR, 0.27).
8
 
These findings support previous data in African refugees resettling to the United States showing similar 
decrease in soil-transmitted helminths following implementation of predeparture albendazole treatment.
7
  
However, despite this documented decrease in the overall prevalence of soil-transmitted helminth infections, 
a single dose of albendazole has very limited effect on infection with Strongyloides and no effect against 
Schistosoma spp.  
Due to documented high rates of infection in refugee populations and increasing reports of serious clinical 
consequences, in 2005 CDC issued recommendations for predeparture treatment for strongyloidiasis (in all 
Middle Eastern, Asian, and African refugees) as well as for schistosomiasis (in SSA refugees only). These 
guidelines advise presumptive treatment for strongyloidiasis with 2 doses of ivermectin for refugees from 
non-Loa loa endemic countries. In addition, as of January 2010, presumptive predeparture treatment for 
schistosomiasis with praziquantel is recommended for SSA refugees who do not have contraindications 
(Table 1). However, institution of these recommendations was variable due to funding restrictions and 
logistical challenges. A table of countries that are currently implementing these pre-departure presumptive 
treatments can be found here.  
Predeparture presumptive treatment  
Certain populations may not receive predeparture presumptive treatment.  In addition, specific individuals 
within in each population may not be eligible for certain predeparture medications due to pregnancy, 
breastfeeding, young age, or other contraindications, such as known hypersensitivity or allergies and history 
of seizures or known neurocysticercosis.  Thus, post-arrival guidelines are designed to be flexible and are 
contingent upon whether the predeparture presumptive treatment was received. Ideally, the clinician will 
have documentation of presumptive therapy received by each individual at the time of new arrival screening.  
However, it is recognized that currently this documentation is not consistently available.  In cases when the 
documentation is not available it is reasonable to assume presumptive treatment has been received by the 
individual refugee if the refugee is from a population where the program is currently implemented and as 
long as they had no contraindications at the time of departure. CDC periodically monitors ongoing programs 
and has documented 75-100% compliance rates in populations that are currently treated. If a country does 
not appear on this table, then compliance rates in that country are uncertain, so the clinician should use their 
judgment regarding screening the refugee or providing  presumptive treatment.    
An algorithm has been developed based on current programming to assist the post-arrival clinician in the 
management of parasites in newly arriving refugees (Figure 1). Presently, the majority of resettling 
populations receive predeparture albendazole making stool testing or treatment for soil-transmitted 
helminths (STH) unnecessary for most refugees.  In addition, the majority of SSA populations have been 
presumptively treated for schistosomiasis with praziquantel; therefore, domestic testing and treatment for 
schistosomiasis are also not necessary for most refugees from SSA.  Refugees arriving from the Middle 
East, Asia, and SSA countries that are not endemic for L. loa, are at high risk for strongyloides infection.  If 
they have not been presumptively treated overseas with ivermectin, they should receive presumptive 
treatment with ivermectin after arrival or undergo testing followed by treatment, if positive.   A table of 
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countries that are currently implementing these pre-departure presumptive treatments can be found here.  It 
is anticipated that the implementation of predeparture presumptive treatment for strongyloidiasis may be 
expanded to other US-bound refugee populations in the future so clinicians should continue to check the 
CDC website for updated information.     
 
Refugees from L. loa endemic SSA countries should not receive presumptive ivermectin due to the possible 
risk of encephalopathy associated with a high load of dying microfilaria.  After arrival in the United States, 
they should undergo testing for strongyloidiasis. Those found to be infected may be treated with a longer 
course of high-dose albendazole (400 mg orally twice a day for 7 days).  Alternatively, they may be 
screened for L. loa with a daytime blood smear and if not infected with L. loa, they can receive presumptive 
treatment with ivermectin.   
 
The following sections recommend approaches for evaluating refugees during the post-arrival domestic 
medical visit based on whether the refugee had documented or presumed predeparture treatment.  For the 
purposes of post-arrival management of parasites, refugees may be divided into three groups: no 
predeparture presumptive treatment, incomplete presumptive treatment, and complete presumptive 
treatment.    
No presumptive treatment  
Refugees in this category did not receive any presumptive treatment for parasites prior to departure for the 
United States.  This group includes persons from populations not included in the table of presumptive 
treatment programs and those excluded due to contraindications to presumptive treatment with albendazole, 
praziquantel, and ivermectin.  An algorithm has been developed to assist clinicians in managing patients 
who have received no predeparture therapy either because they were from a population not included in 
current programming, or if they had a contraindication at the time of departure (Figure 1). 
 
 Albendazole contraindications: 
o Children < 1 year of age, pregnant women, refugees with known neurocysticercosis, 
evidence of cysticercosis (e.g., subcutaneous nodules), or with a history of unexplained 
seizures. 
 Praziquantel contraindications: 
o Children < 4 years of age or measuring < 94 cm, refugees with known neurocysticercosis, 
evidence of cysticercosis (e.g., subcutaneous nodules), or with a history of unexplained 
seizures.  
 Ivermectin contraindications: 
o Children < 15 kg or measuring < 90 cm, pregnant women in any trimester or breastfeeding 
women within the first week after birth. 
 Refugee is departing from or has lived in a Loa loa endemic are: 
Incomplete presumptive treatment  
Refugees in this category did not receive all of the recommended overseas presumptive treatment for 
parasites prior to departure.  An algorithm has been developed to assist clinicians on post-arrival 
management for those who received incomplete therapy (Figure 2). 
 Most refugee populations are receiving single dose albendazole and it is reasonable to assume 
they have received albendazole if they are from populations included in the presumptive treatment 
programs and do not have a contraindication to albendazole.   
 Most SSA refugees, are receiving predeparture praziquantel treatment for schistosomiasis if they 
are from populations included in the presumptive treatment programs and do not have a 
contraindication to praziquantel. 
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Complete presumptive treatment  
Refugees in this category received all recommended treatments for overseas presumptive treatment for 
parasites prior to departure (Figure 3).  A table of countries that are currently implementing these pre-
departure presumptive treatments can be found here. 
Finding information sources on presumptive treatment received  
There have been substantial challenges in providing the records of presumptive parasite treatment for 
individual refugees to US clinicians at the time of their new arrival medical examination.  Therefore, 
information and individual refugee presumptive treatment records are made available in multiple formats.   
 IOM Bag:  Records of presumptive predeparture treatment received by the refugee are usually 
available in the IOM bag, also known as the “blue and white bag,” carried by the refugee.  The 
refugee should be directed to bring the IOM bag to the clinic at the time of appointment.  The 
provider may also check with the voluntary resettlement agency coordinating the refugee’s care as 
they may have a copy of these records. 
 Electronic Disease Notification System (EDN): Records will be made available to Refugee 
Health Coordinators and some clinics through EDN.  Clinicians may request this information from 
their respective state refugee health program. 
 CDC Website:  In addition, refugee populations receiving presumptive treatment will be listed on 
CDC’s website.  A table of countries that are currently implementing these pre-departure 
presumptive treatments can be found here. 
 
 
Summary of management of parasitic infections by population in asymptomatic refugees  
Management of asymptomatic refugees who received no predeparture treatment  
 A refugee who received no overseas predeparture antiparasitic treatment should receive either 
post-arrival presumptive treatment or post-arrival screening.  
 If presumptive treatment is selected, follow the recommendations in Table 1.  If screening is 
selected, follow the algorithm in Figure 1.  
Management of asymptomatic refugees who received incomplete presumptive treatment for 
parasitic infection  
 A refugee who received incomplete presumptive treatment overseas should receive either post-
arrival presumptive treatment or post-arrival screening (Figure 2).   
 If presumptive treatment is selected, follow the recommendations in Table 1.   
Most refugees resettling in the United States who fall into this category have received albendazole and do 
not require routine stool O&P screening or presumptive treatment with albendazole. Although most refugees 
currently receive albendazole therapy, many are not receiving treatment for strongyloidiasis or 
schistosomiasis even though such treatment was indicated.  Depending on which treatment was not 
received, the clinician will need to select the appropriate presumptive treatment or screen and treat strategy. 
Presumptive treatment for strongyloidiasis for refugees from non-Loa loa endemic countries is two doses of 
ivermectin given on two consecutive days (Tables 1). For those from Loa loa endemic areas, a screen and 
treat approach is usually more appropriate, although presumptive high-dose, long-course albendazole with 
or without screening is an acceptable alternative for presumptive treatment of Loa loa (Table 1.). For SSA 
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refugees who have not received predeparture therapy for schistosomiasis, post-arrival presumptive 
treatment with praziquantel (Tables 1) or screening and treatment is indicated.  Serologic testing is the most 
sensitive test for screening.  Details on diagnostic tests available for Strongyloides and schistosomiasis in 
symptomatic patients are discussed below. 
Management of asymptomatic refugees who received complete presumptive treatment for parasitic 
infection  
 There is no need to screen asymptomatic refugees for parasitic infection if they received the 
complete treatment package (Figure 3).   
However, it is common for arriving refugees to have a screening eosinophil count as part of their routine 
complete blood count (CBC) with differential.  If elevated this may indicate infection and follow-up is 
recommended in Figure 3. 
Screening and diagnostic tests for strongyloidiasis  
Screening for strongyloidiasis involves serologic testing or stool culture.  Stool ova and parasite examination 
may be used, but testing of three samples results in less than 60% sensitivity and up to 7 samples may be 
necessary to increase sensitivity to more than 90%.  Serologic testing is the most widely available testing 
modality and positive results are sufficient to confirm the diagnosis.  However, a combination of more than 
one testing technique may increase sensitivity and specificity (e.g., serology and stool ova and parasite 
testing). For SSA refugees who have lived in areas endemic forL. loa, screening for L. loa using a 
quantitative daytime blood smear or filariasis/Loa loa serology is necessary in order to determine the safety 
of ivermectin therapy.  Refugees who are negative may be treated with ivermectin; those who are positive 
may be treated with high dose albendazole.  Testing for Loa loa is not necessary if treating persons with 
strongyloidiasis with high-dose albendazole.  Further information on loiasis is available on the CDC Division 
of Parasitic Diseases Website.   
 
Screening and diagnostic tests for schistosomiasis  
 
Serologic testing is the most sensitive test for screening for schistosomiasis. Stool ova and parasite testing 
may detect infection, although, similar to testing for strongyloidiasis, sensitivity can be quite low. Diagnosis 
of schistosomiasis can be made using stool, urine studies, or serologies.  Refugees at risk for S. 
hematobium should have urine checked for ova.  Schistosoma hematobium is endemic to much of Africa, 
parts of Arabia, the Middle East, and Khuzestan Province in Iran, Madagascar, and Mauritius. Those who 
are from areas endemic for the other schistosome species should have stool checked for ova to detect other 
species such as S. mansoni and S. japonicum.  Standard stool studies are not as sensitive for 
schistosomiasis as for soil-transmitted helminths.  When performing stool testing for schistosomiasis it is 
important to collect three specimens on three separate days.  Although the Kato Katz method(staining a 
stool sample and examining under a microscope) is preferred, formalin preserved stool with concentration 
may also detect schistosome ova.  Urine should also be collected three times on three separate days.  
Hematuria can be used as an indicator of infection in persons from endemic areas in SSA.  Serologic testing 
is useful for diagnosis in populations that have never received praziquantel. Combining serology and stool 
testing may increase sensitivity and specificity in both screening and in diagnosis of disease. In addition, 
other findings on routine screening tests may suggest infection such as eosinophilia (e.g., strongyloidiasis, 
schistosomiasis) or hematuria (e.g., schistosomiasis), although these are non-specific findings.  
 
Further information on individual parasites may be obtained from www.cdc.gov/parasites and assistance 
with diagnosis or management of parasitic diseases may be obtained through the CDC’s Parasitic Diseases 
Branch Public Inquiries Line at parasites@cdc.gov or 404-718-4745.
 
Persistent eosinophilia in refugee populations  
Figure 3 describes management of baseline eosinophilia in an asymptomatic refugee who is tested upon 
resettlement in the United States.  Ideally, the eosinophil count would be checked in refugees only 3-6 
months after receipt of the complete presumptive treatment.  In practice, most refugees receive a baseline 
eosinophil count as part of a CBC with differential done as part of the new arrival medical screening that 
occurs shortly after presumptive predeparture treatment and resettlement in the United States.  If the 
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eosinophil count is normal, repeat testing for eosinophilia in an asymptomatic person is not indicated.   If the 
absolute eosinophil count is > 400 cells/mL clinical decision making should be based on the history of 
presumptive treatment.   
 Refugees who received the complete presumptive treatment package should have their eosinophil 
count repeated in 3-6 months, as it can take this long for eosinophilia to resolve after appropriate 
treatment.  No other testing is indicated in an asymptomatic refugee. 
 If the refugee has not received the complete presumptive treatment package it is reasonable to 
provide the missing components of the complete treatment package (Table 1) and recheck 
eosinophil counts in 3-6 months after receipt of treatment prior to embarking on a diagnostic work-
up.  The most common etiologies of eosinophilia in asymptomatic refugee populations are soil-
transmitted helminths, Strongyloides, and Schistosoma infections. 
 If the refugee has not received the complete presumptive treatment package and the clinician opts 
for screening for parasitic infections in lieu of presumptive treatment, the work-up suggested in 
Figure 1 may be followed.  The most common etiologies of eosinophilia in asymptomatic refugee 
populations are soil-transmitted helminths, Strongyloides, and Schistosoma infections. 
If the eosinophilia persists 6 months after treatment, an evaluation of eosinophilia that includes other 
parasites (other than soil-transmitted helminths, Strongyloides, and Schistosoma infections) as well as non-
parasitic causes should be considered.
18
  
Other parasitic infections commonly encountered in refugees  
There are many parasitic infections encountered in refugees which may be detected as a result of solicited 
symptoms such as abdominal pain (e.g., Hymenolepis nana) or seizures (cystercercosis), physical 
examination (e.g., filariasis, onchocerciasis), laboratory abnormalities such as persistent eosinophilia (e.g., 
liver or lung flukes) or as incidental findings on stool examination (e.g., protozoal infections).  Further 
information on these parasitic infections and assistance with diagnosis and treatment may be provided by 
the Centers for Disease Control and Prevention’s Division of Parasitic Diseases (hyperlink to: 
www.cdc.gov/parasites/). 





Regimens by Pathogen 
 Soil-transmitted helminths: 
Albendazole  
Strongyloidiasis: Ivermectin 





Adults    
Asia, Middle East, 
and North Africa, 
Latin America and 
Caribbean 
400 mg orally for 1 day Ivermectin, 200 g/kg/day 





400 mg orally for 1 day
 
 
Ivermectin, 200 g/kg/day 




mg/kg (may be divided 
and given in two doses 
for better tolerance). 
Sub-Saharan 
Africa, Loa loa- 
endemic area 
400 mg orally for 1 day 
Only use ivermectin (200 
g/kg/day once a day for 2 
days) if Loa loa infection has 
been ruled out. May use high 
dose albendazole (400 mg 
twice a day for 7 days)) if 
Loa loa infection cannot be 
ruled out. For more 
Praziquantel, 40 mg/kg 
(may be divided and 
given in two doses for 
better tolerance). 
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information see screening 
and diagnostic tests for 
strongyloidiasis below.  
Pregnant women    
Asia, the Middle 
East/North Africa, 
Latin America and 
Caribbean 
Not recommended Not recommended Not recommended 
Sub-Saharan 
Africa  
Not recommended Not recommended Praziquantel, 40 mg/kg 
(may be divided and 
given in two doses for 
better tolerance). 
Children    
Asia, the Middle 
East/North Africa, 
Latin America and 
Caribbean  
12-23 months of age: 200 
mg orally for 1 day.
 
Presumptive therapy is not 
recommended for any 
infant less than 12 months 
of age. 
Ivermectin, 200 g/kg/day 
orally once a day for 2 days 
Should not be used 
presumptively if <15 kg or 





12-23 months of age: 200 
mg orally for 1 day.
 
Presumptive therapy is not 
recommended for any 
infant less than 12 months 
of age. 
 
Ivermectin, 200 g/kg/day 
orally once a day for 2 days 
 Should not be used 
presumptively if <15 kg or 




Children under < 4 
years of age should not 
receive presumptive 
treatment with 
praziquantel.  Only for 
children from sub-
Saharan Africa 
Although WHO states ivermectin and albendazole may be given concurrently, it is recommended that 
ivermectin be taken on an empty stomach and albendazole with fatty foods. 
 
Praziquantel, if not co-administered, should be administered at least one day prior to either ivermectin or 
albendazole.
 
Praziquantel should be taken with liquids during a meal. 
 
All sub-Saharan African countries are considered endemic for schistosomiasis except Lesotho. 
 
Table 2.  Common parasites detected on stool examination  
Pathogenic  Controversial Nonpathogenic 






















































Entamoeba coli  
Entamoeba 
hartmanii  




mesnili   
*The cyst of E. histolytica, E. dispar and E. moshkowskii  are morphologically identical by stool microscopy 
(morphologically).  When cysts are detected, stool antigen testing is recommended distinguish the 




Table 3.  Causes of eosinophilia  
Parasites that cause 
eosinophilia commonly 
found in stool 
examination  
Other parasitic infections 
associated with eosinophilia  
Parasites commonly found 






Ascaris lumbricoides  
Hookworm (Ancylostoma 
spp, Necator spp) 
Trichuris trichiura 
Strongyloides stercoralis*  
Tapeworm (Taenia 
solium and T. saginatum) 
Schistosoma (most 
commonly S. mansoni*, 













bancrofti, Brugia spp, 
Mansonella spp, Onchocerca 
volvulus, Dracunculus 
medinensis. Loa loa) 
Schistosoma (most commonly 
S. mansoni*, S. 
haematobium*, S. japonicum*)  
 
Entamoeba spp. 
(histolytica/, dispar, other 
Entamoeba spp.)  
Cryptosporidium spp.   
Giardia intestinalis (also 







Drug allergy  
 
Eosinophilic leukemia  
 









Polyarteritis nodosa  
*Particularly common causes of eosinophilia which may be found in stool but special testing and/or multiple 
samples are frequently needed. 
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Treatment Schedules for Presumptive Parasitic Infections for U.S.-Bound Refugees, administered by IOM
a
—May 2013 
Prepared by Immigrant, Refugee and Migrant Health Branch, Division of Global Migration and Quarantine, CDC 
 
This table describes presumptive anti-parasitic treatment currently provided to the largest groups of U.S.-bound refugees. The first three columns 
list the region, departure country, and ethnicity/national origin of the refugees. The fourth column lists recommended presumptive treatment for 
parasites (including malaria).   
 
a Information provided by the International Organization for Migration (IOM) during required overseas refugee medical exam  
b Presumptive parasite treatments: Albendazole (for soil-transmitted helminths), 400 mg for refugees ≥ 2 yo; Albendazole, 200 mg for those 1-2 yo;  Ivermectin (for strongyloides), 200 µg/kg x 2 d;  and 
Praziquantel (for schistosomiasis), 40 mg/kg divided in 2 doses. See http://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/intestinal-parasites-overseas.html  
Arthemether-lumifantrine (AL, for malaria) 6-dose treatment. See http://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/malaria-guidelines-overseas.html#opI 
c Over 75% compliance rates with administration of presumptive parasite treatment have been documented for the countries listed on this table. If a country does not appear on this table, then 
compliance rates in that country are uncertain, so clinicians should use their judgment on a screening vs. presumptive treatment approach. 
Region Country of Processing 
Principal Refugee Groups 
(location) 
Presumptive Parasite 






Eritreans (Shimelba);  
Somalis (Kebribeya);  














Artemether-lumefantrine since fall 
2007 




Artemether-lumefantrine since July 
2007 






Malaysia Burmese (Kuala Lumpur) 
Albendazole 
Ivermectin  
-Albendazole for children 1-2 yo 
since Nov 2011 
-Ivermectin, since Feb 2013 
Nepal 
Bhutanese (Beldangi, Sanischare, 
Khudunabari); other (urban) 
Albendazole 
Ivermectin 
-Albendazole for children 1-2 yo 
since Feb 2012 
-Ivermectin since Jan 2013 
Thailand 




-Albendazole for children 1-2 yo 
since Oct 2011 
-Ivermectin since July 2011 
Mideast 
Iraq Iraqis (Baghdad, Al Walid camp) Albendazole 
 Jordan Iraqis (Amman) Albendazole 
Lebanon, Syria, Turkey, Egypt Multiple None 
Europe Russia, Ukraine, Moldova 
Russians, Afghanis, Ukrainians, 
Moldovans 
None  
Americas Cuba, other Cubans, Colombians None  
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